Journal Article

Mutational landscape of inflammatory breast cancer

Viens, Patrice, Adélaïde, José, Syed, Najeeb, Guille, Arnaud, Ceccarelli, Michele, Finetti, Pascal, Callens, Céline, Bedognetti, Davide, Bertucci, François, Birnbaum, Daniel, Mamessier, Emilie, Goncalves, Anthony, Lerebours, Florence, Van Laere, Steven

2024

Overview

Background Inflammatory breast cancer (IBC) is the most pro-metastatic form of BC. Better understanding of its enigmatic pathophysiology is crucial. We report here the largest whole-exome sequencing (WES) study of clinical IBC samples. Methods We retrospectively applied WES to 54 untreated IBC primary tumor samples and matched normal DNA. The comparator samples were 102 stage-matched non-IBC samples from TCGA. We compared the somatic mutational profiles, spectra and signatures, copy number alterations (CNAs), HRD and heterogeneity scores, and frequencies of actionable genomic alterations (AGAs) between IBCs and non-IBCs. The comparisons were adjusted for the molecular subtypes. Results The number of somatic mutations, TMB, and mutational spectra were not different between IBCs and non-IBCs, and no gene was differentially mutated or showed differential frequency of CNAs. Among the COSMIC signatures, only the age-related signature was more frequent in non-IBCs than in IBCs. We also identified in IBCs two new mutational signatures not associated with any environmental exposure, one of them having been previously related to HIF pathway activation. Overall, the HRD score was not different between both groups, but was higher in TN IBCs than TN non-IBCs. IBCs were less frequently classified as heterogeneous according to heterogeneity H-index than non-IBCs (21% vs 33%), and clonal mutations were more frequent and subclonal mutations less frequent in IBCs. More than 50% of patients with IBC harbored at least one high-level of evidence (LOE) AGA (OncoKB LOE 1–2, ESCAT LOE I–II), similarly to patients with non-IBC. Conclusions We provide the largest mutational landscape of IBC. Only a few subtle differences were identified with non-IBCs. The most clinically relevant one was the higher HRD score in TN IBCs than in TN non-IBCs, whereas the most intriguing one was the smaller intratumor heterogeneity of IBCs.

• Publisher: BioMed Central,BioMed Central Ltd,BMC
• Subject: Analysis / Biomedical and Life Sciences / Biomedicine / Breast cancer / Breast Neoplasms - genetics / Care and treatment / Copy number alteration / Development and progression / Diagnosis / DNA sequencing / Female / Gene mutations / Genetic aspects / Genomics / Health aspects / Humans / Inflammatory breast cancer / Inflammatory Breast Neoplasms - genetics / Inflammatory Breast Neoplasms - pathology / Life Sciences / Medicine/Public Health / Metastasis / Mutation / Mutation - genetics / Network Medicines / Nucleotide sequencing / Retrospective Studies / Whole-exome sequencing